A medicant delivery device for masking taste of a medicant for facilitating oral delivery to an animal includes a shell, which defines an interior space. The shell has a top, which is open for insertion of a medicant therethrough into the interior space. The shell comprises one or more of protein, fat, and vegetable matter, so that the shell is both edible and formable. The shell is at least one of compressible and foldable, proximate to the top, to encase and substantially seal the medicant within the shell. The shell containing the medicant is delivered orally to an animal to medicate the animal.

The present disclosure relates to methods of treating pain in veterinary subjects using pharmaceutical compositions and dosage forms comprising hemp extract. In an aspect, provided herein is a pharmaceutical composition comprising hemp extract and a carrier, wherein the hemp extract comprises cannabidiol; and cannabidiolic acid; wherein the ratio of cannabidiol to cannabidiolic acid is about 0.6:1 to about 1:0.6.

The present disclosure relates to methods of treating pain in veterinary subjects using pharmaceutical compositions and dosage forms comprising hemp extract. In an aspect, provided herein is a pharmaceutical composition comprising hemp extract and a carrier, wherein the hemp extract comprises cannabidiol; and cannabidiolic acid; wherein the ratio of cannabidiol to cannabidiolic acid is about 0.6:1 to about 1:0.6.

Novel products formulated for use as nutritional supplements are designed to enhance oral health and immune function in mammals. An exemplary composition can be customized by adding nutritional or therapeutic ingredients according to a health condition or medical requirement. Oral formulations are described which can be used as dietary supplements on a daily basis to effectively prevent plaque formation in the oral cavity in addition to providing immune protection mediated by enhancing saliva secretions.

The present invention discloses a system and method for increasing the lifespan and quality of life of human beings and other mammals. This discloses methods for preparing and delivering various health and longevity compositions. The compositions of the present invention are selected and designed for the purpose of efficiently delivering health and longevity enhancing therapies through oral supplementation, misting, nasal spray, suppository, etc. An existing compound known to have capacity for life extending potential, rapamycin, is combined with a non-toxic therapeutic anabolic hormone, e.g., DHEA, and cannabidiol (CBD) to enable absorption and effect. These three compounds work together to dramatically improve both the quality of life in aging humans and other mammals as well as extending the life of humans potentially up to 120 healthy years. One preferred embodiment provides a method for continuous low dose supplementation, e.g., incorporated in or with a daily meal. This invention not only resolves the issue of anti-aging of higher life forms, without toxicity, but provides for an improved method for absorption.

The present invention relates to methods and compositions for diagnosing and treating degenerative mitral valve disease in a canine. In one embodiment, a method of diagnosing early stage degenerative mitral valve disease in a canine can comprise measuring a normalized relative abundance of a biomarker selected from the group consisting of Erysipelatoclostridium, Ruminococcaceae UCG014, Butyricicoccus, Faecalibacterium, and combinations thereof, and determining that the canine has early stage degenerative mitral valve disease if the Erysipelatoclostridium is from 0 to 0.5 normalized relative abundance, the Ruminococcaceae UCG014 is from 0 to 0.1 normalized relative abundance, the Butyricicoccus is from 0 to 0.1 normalized relative abundance, or the Faecalibacterium is from 0 to 0.1 normalized relative abundance.

The present invention relates to methods and compositions for diagnosing and treating degenerative mitral valve disease in a canine. In one embodiment, a method of diagnosing early stage degenerative mitral valve disease in a canine can comprise measuring a normalized relative abundance of a biomarker selected from the group consisting of Erysipelatoclostridium, Ruminococcaceae UCG014, Butyricicoccus, Faecalibacterium, and combinations thereof, and determining that the canine has early stage degenerative mitral valve disease if the Erysipelatoclostridium is from 0 to 0.5 normalized relative abundance, the Ruminococcaceae UCG014 is from 0 to 0.1 normalized relative abundance, the Butyricicoccus is from 0 to 0.1 normalized relative abundance, or the Faecalibacterium is from 0 to 0.1 normalized relative abundance.

The invention concerns the method and the use of an antimicrobial composition consisting of: (i) at least 30% of lactic acid, and (ii) at least two carboxylic acids selected from the group consisting of acetic acid, butyric acid, isobutyric acid, valeric acid, and isovaleric acid for providing an antimicrobial activity against one or more undesired microorganisms to a pet food product.

Disclosed are probiotic formulations comprising fortified avian eggs and avian egg products such as egg powder, and methods for producing the same substantially no meat containing growth media such as MRS. The formulations may be used to supplement food that include, but are not limited to, baby foods, milk, and pet foods. Effective amounts of the fortified egg formulations comprising at least about 10.sup.9 CFU/dosage of probiotics may be used to treat health issues that include, but are not limited to, irritable bowel syndrome. The probiotic formulation may comprise bacterial strains comprising at least one of L. casei, L. rhamnosus, B. breve, Bifidobacterium longum, L. acidophilus, L. plantarum, B. bifidum, L. fermentum, L. lactis, L. paracasei, and L. salivarius.

Disclosed are probiotic formulations comprising fortified avian eggs and avian egg products such as egg powder, and methods for producing the same substantially no meat containing growth media such as MRS. The formulations may be used to supplement food that include, but are not limited to, baby foods, milk, and pet foods. Effective amounts of the fortified egg formulations comprising at least about 10.sup.9 CFU/dosage of probiotics may be used to treat health issues that include, but are not limited to, irritable bowel syndrome. The probiotic formulation may comprise bacterial strains comprising at least one of L. casei, L. rhamnosus, B. breve, Bifidobacterium longum, L. acidophilus, L. plantarum, B. bifidum, L. fermentum, L. lactis, L. paracasei, and L. salivarius.